Maynard Um
-
-
-
-
-
-
-
Atossa Therapeutics gets FDA clearance for breast cancer drug study
-
-
-
-
-
-
-
Atossa highlights potential for endoxifen in muscular dystrophy treatment
-
-
-
-
-
-
-
Atossa requests FDA meeting for endoxifen breast cancer drug development
-
-
-
-
-
-
-
Atossa Genetics (ATOS) Tops Q1 EPS by 2c
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer
401,066 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

